Lipitor prepares for fadeout after US$130bil sales


  • Business Premium
  • Monday, 07 Nov 2011

NEW YORK (Reuters) - It may take a breakthrough treatment for Alzheimer's disease to match the $130 billion lifetime sales record of Pfizer's Lipitor, the cholesterol fighter that wrote its own chapter in pharmaceutical history.

Lipitor's U.S. patent expires on November 30, unleashing a wave of cheap generics and ending a fabled run that began in 1997.

Article type: metered
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights
   

Next In Business News

Ekuinas’ total cumulative investment at RM4.4bil in FY21 Premium
Inflation low and under control due to subsidies, price controls: Mustapa Premium
Bank Indonesia keeps rates unchanged to underpin recovery Premium
Asia stocks skid with U.S. futures, euro holds gains Premium
Oil prices fall on concerns over recession, China Covid curbs Premium
Citi Malaysia bags best bond award in Asia by Asset Magazine Premium
Pestech partners French company to explore green hydrogen projects Premium
Sime Darby's net profit falls to RM244mil in 3Q Premium
FBM KLCI descends into the red as negative sentiment continues Premium
KNM to dispose of Borsig in RM1.03bil deal Premium

Others Also Read